USANA Health Sciences: Earnings, Revenue, and Analyst Forecasts
A breakdown of USNA's financials, analyst estimates, and stock performance for traders watching the health sciences sector.
USANA Health Sciences (NYSE: USNA) is back on traders' radar as fresh actuals and forward estimates hit the tape. The direct-selling nutrition company carries a niche profile — not a household name on Wall Street, but its numbers move the stock, and right now those numbers matter.
The financial snapshot covers the key metrics you care about: earnings per share against analyst expectations, quarterly revenue trends, and net income direction. When a mid-cap like USNA beats or misses, the price reaction can be sharp — thin institutional coverage means fewer shock absorbers on volatile print days.
Read more OpenAI IPO Odds: Traders Bet on 2027 Over 2026 →
Analyst estimates give you the forward map. Watch where consensus EPS sits relative to the last few actuals. If USNA has been consistently beating a low bar, that's a setup worth knowing. If estimates are creeping down while management stays quiet, that's a warning flag you don't ignore.
Historical price data rounds out the picture, letting you frame current levels against prior earnings cycles. Context is everything — a stock trading near a post-earnings low on improving fundamentals tells a very different story than one grinding near all-time highs into a shaky print.
Bottom line: USNA is a stock where doing your homework on the estimate revisions and revenue trajectory pays off before you size into any position. Continue reading at TradingView.
